Ticrynafen and probenecid in hyperuricemic, hypertensive men

Publisher Website
Google Scholar
Abstract
In a double-blind crossover study of ticrynafen (TCN, 2,3-dichloro-4-(2-thyenylcarbonyl) phenoxyacetic acid) and probenecid (PBC), 9 hypertensive, hyperuricemic men completed 12 wk courses of each drug. With a TCN dose of 125 mg daily, the fall in serum uric acid was prompt, dramatic and lasting; it was equal to that after PBC, 500 or 1000 mg daily. There was a small but significant early weight loss (diuresis) after TCN but no antihypertensive effect. After 12 days of resuming TCN for a proposed additional extension study 1 patient suffered acute, reversible bilateral ureteral obstruction, probably due to sudden urinary uric acid precipitation.